Funding for this research was provided by:
Cure SMA Industry Collaboration
Article History
Received: 5 June 2023
Accepted: 21 September 2023
First Online: 19 October 2023
Declarations
:
: Jill Jarecki is currently an employee of BioMarin Pharmaceuticals and was an employee of Cure SMA at the time of this study. Lisa Belter and Ilse Peterson declare that they have no competing interests.
: Institutional review board (IRB) approval was obtained from Western IRB on November 24, 2020 (IRB ID: 20203852). Consent was assumed from a respondent’s survey participation. The study was performed in accordance with the Helsinki Declaration of 1964.